Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Immatics
Thumbnail
February 25, 2022

Crunch time for the Spac space

This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.

Thumbnail
February 22, 2022

Biontech follows Immatics and goes after Prame

Article image
Vantage logo
December 06, 2021

Adicet scores the first hit for gamma-delta

Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.

Article image
Vantage logo
December 06, 2021

Benevolent AI aims to defy Spac doom

Article image
Vantage logo
November 09, 2021

SITC 2021 – Immatics’ T-cell receptor success was no fluke

Article image
Vantage logo
July 12, 2021

Spac listings slow as the hunt for deals continues

Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.

Article image
Vantage logo
May 19, 2021

Iovance delayed again

Article image
Vantage logo
March 17, 2021

Immatics takes up the Spac baton

First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.

Article image
Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.

Article image
Vantage logo
October 06, 2020

Iovance delayed TIL when?

Article image
Vantage logo
September 29, 2020

More biotechs test the third way to market

Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.